Ratings by Goldman Sachs (Rajan Sharma)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 4/22/2026 | Genmab A/S | GMAB | Upgrade | Buy (Neutral) |
27.91 (25.94) |
-7.06% | Details | |
| 4/22/2026 | Valneva SE | VALN | Downgrade | Sell (Neutral) |
6.04 (5.40) |
-10.6% | Details | |
| 4/9/2026 | DBV Technologies S.A | DBVT | Maintain | Sell (N/A) |
|
Details | ||
| 5/29/2025 | DBV Technologies S.A | DBVT | New Coverage | Sell (N/A) |
9.29 (16.11) |
73.41% | Details | |
| 3/28/2025 | AstraZeneca | AZN | Maintain | Conviction Buy (N/A) |
|
Details | ||
| 2/10/2025 | AstraZeneca | AZN | Maintain | Buy (N/A) |
|
Details | ||
| 11/26/2024 | Immatics | IMTX | New Coverage | Buy (N/A) |
7.59 (9.91) |
30.57% | Details | |
| 11/20/2024 | Immunocore Holdings | IMCR | Maintain | Buy (N/A) |
|
Details | ||
| 8/2/2024 | DBV Technologies S.A | DBVT | Maintain | Sell (N/A) |
|
Details | ||
| 5/30/2024 | AstraZeneca | AZN | New Coverage | Buy (N/A) |
76.62 (92.77) |
21.08% | Details | |
| 5/30/2024 | GlaxoSmithKline | GSK | New Coverage | Neutral (N/A) |
44.24 (52.07) |
17.7% | Details | |
| 5/9/2024 | DBV Technologies S.A | DBVT | Maintain | Sell (N/A) |
|
Details | ||
| 3/14/2024 | DBV Technologies S.A | DBVT | Maintain | Sell (N/A) |
|
Details | ||
| 11/2/2023 | DBV Technologies S.A | DBVT | Maintain | Sell (N/A) |
|
Details | ||
| 9/15/2023 | MorphoSys AG | MOR | Upgrade | Neutral (Sell) |
7.92 (18.96) |
139.39% | Details | |
| 12/16/2022 | Immunocore Holdings | IMCR | New Coverage | Buy (N/A) |
58.96 (29.20) |
-50.47% | Details | |
| 12/16/2022 | DBV Technologies S.A | DBVT | Downgrade | Sell (Neutral) |
1.53 (9.29) |
507.19% | Details | |
| 12/16/2022 | MorphoSys AG | MOR | Downgrade | Sell (Neutral) |
4.08 (18.96) |
364.71% | Details |
